# CGTX (Cognition Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Cognition Therapeutics, Inc. reported $34.80M in total assets and a net loss of $15.99M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/CGTX
- Markdown: https://convexityos.com/fundamentals/CGTX.md
- SEC CIK: 0001455365
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:51 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001455365&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$37.60M | Operating profit |
| Net Income | FY 2025 | -$15.99M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$0.17 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $30.76M | Total debt: $489K |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $37.19M | $41.68M | $37.20M | $30.32M | $18.57M | $12.89M |
| Total Operating Expenses | $47.80M | $53.97M | $50.72M | $43.55M | $28.60M | $17.41M |
| **Operating Income** | -$47.80M | -$53.97M | -$50.72M | -$43.55M | -$28.60M | -$17.41M |
| **EBITDA** | -$47.76M | -$53.86M | -$50.63M | -$43.47M | -$28.50M | -$17.31M |
| Interest Expense | -- | -- | -- | -- | $895K | $1.76M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | -- |
| **Net Income** | -$23.49M | -$33.97M | -$25.79M | -$21.40M | -$11.72M | -$7.84M |
| Basic EPS | -$0.32 | -$0.86 | -$0.86 | -$0.91 | -$3.13 | -$76.84 |
| **Diluted EPS** | -$0.32 | -$0.86 | -$0.86 | -$0.91 | -$3.13 | -$76.84 |
| Basic Shares Outstanding | 72.8M | 39.7M | 30.0M | 23.6M | 5.2M | 157.1K |
| Diluted Shares Outstanding | 72.8M | 39.7M | 30.0M | 23.6M | 5.2M | 157.1K |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $5.12M | $5.10M | $6.12M | $11.15M | $3.77M | $11.48M | $10.79M | $8.15M |
| Total Operating Expenses | $7.38M | $7.74M | $8.82M | $13.67M | $6.38M | $13.98M | $13.78M | $10.72M |
| **Operating Income** | -$7.38M | -$7.74M | -$8.82M | -$13.67M | -$6.38M | -$13.98M | -$13.78M | -$10.72M |
| **EBITDA** | -- | -- | -- | -- | -- | -- | -- | -$10.70M |
| **Net Income** | -$4.14M | -$3.93M | -$4.57M | -$3.34M | -$4.93M | -$6.73M | -$8.48M | -$7.84M |
| Basic EPS | -$0.04 | -$0.04 | -$0.05 | -- | -$0.06 | -$0.11 | -$0.14 | -- |
| **Diluted EPS** | -$0.04 | -$0.04 | -$0.05 | -- | -$0.06 | -$0.11 | -$0.14 | -- |
| Basic Shares Outstanding | 95.1M | 90.6M | 89.2M | -- | 78.0M | 63.7M | 61.8M | -- |
| Diluted Shares Outstanding | 95.1M | 90.6M | 89.2M | -- | 78.0M | 63.7M | 61.8M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $36.81M | $25.01M | $29.92M | $41.56M | $54.72M | $5.19M |
| **Cash & Short-Term Investments** | $36.81M | $25.01M | $29.92M | $41.56M | $54.72M | $5.19M |
| Other Current Assets | -- | -- | -- | -- | $11K | $23K |
| **Total Current Assets** | $47.99M | $29.55M | $34.22M | $47.65M | $58.99M | $6.91M |
| Property, Plant & Equipment, Net | $93K | $181K | $284K | $233K | $145K | $211K |
| **Total Non-Current Assets** | $399K | $679K | $941K | $2.78M | $145K | $211K |
| **Total Assets** | $48.39M | $30.23M | $35.16M | $50.42M | $59.14M | $7.12M |
| Accounts Payable | $1.12M | $1.98M | $3.69M | $3.22M | $4.17M | $2.00M |
| Other Current Liabilities | $307K | $279K | $544K | $634K | $1.19M | $253K |
| **Total Current Liabilities** | $13.92M | $11.14M | $10.17M | $7.79M | $7.86M | $3.25M |
| Other Non-Current Liabilities | -- | -- | $0 | $1.69M | $0 | -- |
| **Total Non-Current Liabilities** | $195K | $342K | $520K | $2.38M | $0 | $16.68M |
| **Total Liabilities** | $14.12M | $11.48M | $10.69M | $10.18M | $7.86M | $19.93M |
| **Total Debt (incl. Leases)** | $331K | $535K | $694K | $844K | -- | -- |
| Common Stock | $90K | $60K | $32K | $29K | $22K | $1.0K |
| Retained Earnings | -$198.6M | -$175.2M | -$141.2M | -$115.4M | -$94.00M | -$68.22M |
| Accumulated Other Comp. Income | -- | -- | -$195K | -$199K | -$198K | -$187K |
| **Total Stockholders' Equity** | $34.27M | $18.75M | $24.47M | $40.25M | $51.27M | -$68.18M |
| Total Equity | $34.27M | $18.75M | $24.47M | $40.25M | $51.27M | -$68.18M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $30.76M | $34.01M | $31.13M | $36.81M | $39.33M | $10.74M | $16.43M | $25.01M |
| **Cash & Short-Term Investments** | $30.76M | $34.01M | $31.13M | $36.81M | $39.33M | $10.74M | $16.43M | $25.01M |
| **Total Current Assets** | $34.24M | $38.30M | $35.81M | $47.99M | $42.88M | $19.05M | $22.87M | $29.55M |
| Property, Plant & Equipment, Net | $76K | $87K | $77K | $93K | $159K | $174K | $190K | $181K |
| **Total Non-Current Assets** | $564K | $597K | $326K | $399K | $512K | $573K | $634K | $679K |
| **Total Assets** | $34.80M | $38.90M | $36.14M | $48.39M | $43.40M | $19.62M | $23.50M | $30.23M |
| Accounts Payable | $445K | $673K | $3.85M | $1.12M | $827K | $771K | $1.82M | $1.98M |
| Other Current Liabilities | -- | $78K | $194K | $307K | -- | $41K | $161K | $279K |
| **Total Current Liabilities** | $5.13M | $5.45M | $6.05M | $13.92M | $6.65M | $12.36M | $10.95M | $11.14M |
| **Total Non-Current Liabilities** | $398K | $422K | $176K | $195K | $212K | $229K | $280K | $342K |
| **Total Liabilities** | $5.53M | $5.87M | $6.23M | $14.12M | $6.87M | $12.59M | $11.23M | $11.48M |
| **Total Debt (incl. Leases)** | $489K | $511K | $271K | $331K | $380K | $427K | $474K | $535K |
| Common Stock | $95K | $95K | $90K | $90K | $88K | $65K | $62K | $60K |
| Retained Earnings | -$211.3M | -$207.1M | -$203.2M | -$198.6M | -$195.3M | -$190.4M | -$183.6M | -$175.2M |
| **Total Stockholders' Equity** | $29.28M | $33.02M | $29.91M | $34.27M | $36.53M | $7.03M | $12.27M | $18.75M |
| Total Equity | $29.28M | $33.02M | $29.91M | $34.27M | $36.53M | $7.03M | $12.27M | $18.75M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$23.49M | -$33.97M | -$25.79M | -$21.40M | -$11.72M | -$7.84M |
| Depreciation & Amortization | $36K | $107K | $96K | $83K | $93K | $98K |
| Stock-Based Compensation | $2.09M | $3.75M | $4.35M | $3.57M | $5.18M | $475K |
| Change in Payables | -- | -- | -- | -$1.09M | $2.17M | -$364K |
| **Operating Cash Flow** | -$24.59M | -$28.47M | -$16.02M | -$18.53M | -$3.63M | -$3.43M |
| Capital Expenditure | -- | -$4.0K | -$147K | -$171K | -$27K | -$10K |
| **Free Cash Flow** | -- | -$28.48M | -$16.16M | -$18.70M | -$3.66M | -$3.44M |
| **Investing Cash Flow** | $9.0K | -$4.0K | -$147K | -$171K | -$27K | -$10K |
| **Financing Cash Flow** | $36.57M | $23.57M | $4.52M | $5.55M | $53.20M | $5.76M |
| **Net Change in Cash** | $11.99M | -$4.91M | -$11.64M | -$13.16M | $49.53M | $2.30M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$4.14M | -$3.93M | -$4.57M | -$3.34M | -$4.93M | -$6.73M | -$8.48M | -$7.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- | -- | -- | $27K |
| Stock-Based Compensation | $348K | $319K | $330K | $358K | $522K | $621K | $586K | $534K |
| **Operating Cash Flow** | -$3.26M | -$3.05M | -$5.54M | -$3.44M | -$5.65M | -$5.62M | -$9.88M | -$8.38M |
| **Financing Cash Flow** | -$28K | $6.61M | -$233K | $605K | $33.92M | $752K | $1.30M | $11.38M |
| **Net Change in Cash** | -$3.29M | $3.54M | -$5.78M | -$2.82M | $28.27M | -$4.87M | -$8.58M | $3.00M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -68.5% | -181.2% | -105.4% | -53.2% | -22.9% | -- |
| Return on Assets (ROA) | -48.5% | -112.4% | -73.3% | -42.4% | -19.8% | -110.1% |
| Current Ratio | 3.45x | 2.65x | 3.37x | 6.11x | 7.50x | 2.13x |
| Quick Ratio | 2.64x | 2.24x | 2.94x | 5.33x | 6.96x | 1.60x |
| Debt to Equity | 0.01x | 0.03x | 0.03x | 0.02x | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -54.6% | -50.8% | -65.5% | -68.5% | -76.6% | -469.4% | -271.4% | -181.2% |
| Return on Assets (ROA) | -45.9% | -43.1% | -54.2% | -48.5% | -64.5% | -168.1% | -141.7% | -112.4% |
| Current Ratio | 6.68x | 7.03x | 5.92x | 3.45x | 6.44x | 1.54x | 2.09x | 2.65x |
| Quick Ratio | 6.00x | 6.24x | 5.14x | 2.64x | 5.91x | 0.87x | 1.50x | 2.24x |
| Debt to Equity | 0.02x | 0.02x | 0.01x | 0.01x | 0.01x | 0.06x | 0.04x | 0.03x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
